News
Therapy for rare cancers: NCT scientists from Heidelberg and Dresden receive the Paul Martini Prize
Joint press release by the NCT Heidelberg and the NCT/UCC Dresden
First set of standards developed for classification of somatic genetic variants in neoplasms
Under the leadership of scientists from the Department of Translational Medical Oncology at the NCT...
DKFZ/NCT/DKTK-MASTER study: Molecular analysis supports therapy decisions in rare cancers
Joint press release of NCT Heidelberg and NCT/UCC Dresden
CCE-DART project - the next generation of clinical trials
The EU-funded project CCE-DART (CCE Building Data Rich Clinical Trials) aims to establish cancer...
New mechanism of action: A small-molecule degrades a cancer-promoting protein by gluing it into filaments
“Molecular glue degraders” are a new class of cancer drugs, which “glue” cancer growth-promoting...
The Virtual Keynote Session on Translational Cancer Research 2020: Empty chairs but still a great success
The prestigious European cancer association Cancer Core Europe (CCE) joint forces again with its...
The European path to personalised oncology: cancer researchers develop a web-based application for the interpretation of complex data
The increasing number of biomarkers makes the decision for cancer treatment more complex. A new...
Molecular glue degraders – a new weapon to target “undruggable” cancer drivers
One strategy to fight cancer is to target its Achilles' heel – the addiction to growth-promoting...
Targeted approach to therapy for rare type of bone cancer
Chordomas are rare bone tumors for which only few options of treatment exist. Scientists and doctors...
Resolution on molecular tumor boards (MTB)
The Directorate of NCT Heidelberg enacts guidelines for the organization of molecular tumor boards...
Therapy for rare cancers: NCT scientists from Heidelberg and Dresden receive the Paul Martini Prize
Joint press release by the NCT Heidelberg and the NCT/UCC Dresden
First set of standards developed for classification of somatic genetic variants in neoplasms
Under the leadership of scientists from the Department of Translational Medical Oncology at the NCT...
DKFZ/NCT/DKTK-MASTER study: Molecular analysis supports therapy decisions in rare cancers
Joint press release of NCT Heidelberg and NCT/UCC Dresden
CCE-DART project - the next generation of clinical trials
The EU-funded project CCE-DART (CCE Building Data Rich Clinical Trials) aims to establish cancer...
New mechanism of action: A small-molecule degrades a cancer-promoting protein by gluing it into filaments
“Molecular glue degraders” are a new class of cancer drugs, which “glue” cancer growth-promoting...
The Virtual Keynote Session on Translational Cancer Research 2020: Empty chairs but still a great success
The prestigious European cancer association Cancer Core Europe (CCE) joint forces again with its...
The European path to personalised oncology: cancer researchers develop a web-based application for the interpretation of complex data
The increasing number of biomarkers makes the decision for cancer treatment more complex. A new...
Molecular glue degraders – a new weapon to target “undruggable” cancer drivers
One strategy to fight cancer is to target its Achilles' heel – the addiction to growth-promoting...
Targeted approach to therapy for rare type of bone cancer
Chordomas are rare bone tumors for which only few options of treatment exist. Scientists and doctors...
Resolution on molecular tumor boards (MTB)
The Directorate of NCT Heidelberg enacts guidelines for the organization of molecular tumor boards...